{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:00:48Z","timestamp":1792404048319,"version":"4.4.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.heliyon.2023.e22015","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T02:15:13Z","timestamp":1699841713000},"page":"e22015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS\/MS) and enzyme-multiplied immunoassay technique (EMIT) for quantification of voriconazole plasma concentration from Chinese patients"],"prefix":"10.1016","volume":"9","author":[{"given":"Mingjie","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lirong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipeng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.heliyon.2023.e22015_bib1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2023.e22015_bib2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22015_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22015_bib4","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/bcp.14578","article-title":"Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: a prospective observational study","volume":"87","author":"Tang","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e22015_bib5","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22015_bib6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"10273","key":"10.1016\/j.heliyon.2023.e22015_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e22015_bib8","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e22015_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1155\/2014\/340586","article-title":"Therapeutic drug monitoring for triazoles: a needs assessment review and recommendations from a Canadian perspective","volume":"25","author":"Laverdiere","year":"2014","journal-title":"Can. J. Infect Dis. Med. Microbiol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e22015_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10156-013-0607-8","article-title":"Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"19","author":"Hamada","year":"2013","journal-title":"J. Infect. Chemother."},{"issue":"12b","key":"10.1016\/j.heliyon.2023.e22015_bib11","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/imj.12600","article-title":"Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy","volume":"44","author":"Chau","year":"2014","journal-title":"Intern. Med. J."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e22015_bib12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/FTD.0000000000000561","article-title":"Individualized medication of voriconazole: a practice guideline of the division of therapeutic drug monitoring, Chinese pharmacological society","volume":"40","author":"Chen","year":"2018","journal-title":"Ther. Drug Monit."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22015_bib13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12291-015-0507-z","article-title":"Plasma voriconazole estimation by HPLC","volume":"31","author":"Chawla","year":"2016","journal-title":"Indian J. Clin. Biochem."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e22015_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5356","article-title":"UPLC-MS\/MS method for the determination of voriconazole plasma concentration from pediatric patients with hematologic tumors: an application toward personalized therapy","volume":"36","author":"Wen","year":"2022","journal-title":"Biomed. Chromatogr."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e22015_bib15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1177\/00045632211041887","article-title":"Comparison of ultra-performance liquid chromatography and ARK immunoassay for therapeutic drug monitoring of voriconazole","volume":"58","author":"Pena-Lorenzo","year":"2021","journal-title":"Ann. Clin. Biochem."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e22015_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/00365513.2020.1868048","article-title":"Correlation between enzyme multiplied immunoassay technique and high-performance liquid chromatography in the quantification of voriconazole in a paediatric population","volume":"81","author":"Li","year":"2021","journal-title":"Scand. J. Clin. Lab. Invest."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e22015_bib17","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: a meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e22015_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13121991","article-title":"Recent advances in therapeutic drug monitoring of voriconazole, mycophenolic acid, and vancomycin: a literature review of pediatric studies","volume":"13","author":"Resztak","year":"2021","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e22015_bib19","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/FTD.0000000000000861","article-title":"Comparison of a point-of-care testing with enzyme-multiplied immunoassay technique and liquid chromatography combined with tandem mass spectrometry methods for therapeutic drug monitoring of mycophenolic acid: a preliminary study","volume":"43","author":"Zhou","year":"2021","journal-title":"Ther. Drug Monit."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e22015_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22587","article-title":"Comparison of whole-blood tacrolimus concentrations measured by different immunoassay systems","volume":"32","author":"Kaneko","year":"2018","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.heliyon.2023.e22015_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.750744","article-title":"Switching between LC-ESI-MS\/MS and EMIT methods for routine TDM of valproic acid in pediatric patients with epilepsy: what clinicians and researchers need to know","volume":"12","author":"Xia","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22015_bib22","first-page":"266","article-title":"Comparative study between high performance liquid chromatography and enmyme-amplified immunoassay method for monitoring voriconazole concentration in human plasma","volume":"29","author":"Ding","year":"2020","journal-title":"Chinese Journal of Clinical Pharmacy"},{"issue":"22","key":"10.1016\/j.heliyon.2023.e22015_bib23","first-page":"56","article-title":"Correlation analysis of voriconazole plasma concentrations detected by HPLC and EMIT","volume":"31","author":"Zhuo","year":"2022","journal-title":"China Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e22015_bib24","doi-asserted-by":"crossref","first-page":"e421","DOI":"10.1111\/j.1439-0507.2010.01938.x","article-title":"Comparison and evaluation of a novel bioassay and high-performance liquid chromatography for the clinical measurement of serum voriconazole concentrations","volume":"54","author":"Steinmann","year":"2011","journal-title":"Mycoses"},{"key":"10.1016\/j.heliyon.2023.e22015_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.106078","article-title":"Therapeutic drug monitoring and safety of voriconazole in elderly patients","volume":"78","author":"Cheng","year":"2020","journal-title":"Int. Immunopharm."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402309223X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402309223X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:27:45Z","timestamp":1791293265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584402309223X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S240584402309223X"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e22015","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS\/MS) and enzyme-multiplied immunoassay technique (EMIT) for quantification of voriconazole plasma concentration from Chinese patients","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e22015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e22015"}}